Musculoskeletal immune-related adverse events with use of checkpoint inhibitors in malignancy.

Rheumatic irAEs are heterogenous clinical entities which require further evaluation into classification, patient susceptibility and response. From our study, there was no clear clinical pattern. Our case series supports that rheumatic irAE may be associated with tumour response. However, there is still limited experience in rheumatic irAEs management and outcomes. This article is protected by copyright. All rights reserved.